Cooley Recognized With Three 2023 China Business Law Awards // Leave a comment
Beijing, Hong Kong and Shanghai – July 10, 2023 – China Business Law Journal has honored Cooley as part of its 2023 China Business Law Awards, which recognizes the best Chinese and international law firms in various practice area categories for the Chinese market. The firm has been included annually among the top international law firms in CBLJ’s Asset Management category since 2021, and in the Private Equity and Venture Capital and Healthcare, Pharma and Life Sciences categories since 2019.
With nearly 20 members based in our Beijing, Shanghai and Hong Kong offices, Cooley’s fund formation practice regularly provides industry-leading fund formation services to top-tier VC and other funds active in the US and Asia. The award recognition for asset management reflects the firm’s role in the past year assisting 30+ institutions with more than 40 fund formation and related deals in China and other parts of Asia.
CBLJ also recognized Cooley for its balanced performance representing VC investors and companies. The firm’s China team was involved in more than 100 private equity and VC financing transactions last year, with particularly strong focus on the life sciences, healthcare, fintech, new consumer, edtech, software as a service (SaaS), big data, artificial intelligence, online retail and other high-tech sectors.
In addition, the firm’s excellence and leadership in the life sciences and healthcare sector was positively noted by CBLJ. Along with the aforementioned private equity and VC deals we completed in 2022, we counseled clients on a number of other cross-border transactions throughout their life cycle. In the past year, we have helped innovative life sciences and healthcare companies – including InxMed, Pulnovo Medical, Lupeng Pharmaceutical and Full-Life Technologies – close multiple rounds of strategic financing from early to late stages. We have also advised leading biotechnology companies and investors, such as Vivo Capital, InnoRNA, Zai Lab and IASO Bio, on more than 10 high-profile cross-border licensing and partnering transactions, and we’ve acted as counsel to issuers and underwriters, respectively, in a series of capital markets projects, including the follow-on offering of Legend Biotech and the Hong Kong IPO of Cryofocus Medtech.
One of the firm’s company clients in the life sciences sector told CBLJ that “the Cooley team consistently provided us with first-rate client service that reflects solid technical skills, outstanding problem-solving capabilities, and unparalleled professionalism.”
Cooley’s Beijing, Hong Kong and Shanghai offices represent a growing number of China’s most innovative and dynamic tech and life sciences companies, advising them from formation through financings and exits. The team’s in-depth subject matter knowledge and transactional prowess enable the firm to handle a raft of corporate, finance, M&A, and capital markets work for international and China-based high-tech and life sciences entities engaged in inbound and outbound endeavors.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
